Enveric Biosciences, Inc. 是一家製藥公司,致力於開發各種用於治療癌症的大麻素藥物。公司總部位於佛羅里達州那不勒斯。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
營業支出
2026-06-30
$2.99M
2026-03-31
$1.59M
2025-12-31
$2.15M
2025-09-30
$1.83M
淨利潤
2026-06-30
-$3.02M
2026-03-31
-$1.63M
2025-12-31
-$2.19M
2025-09-30
-$1.87M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-0.76
2026-03-31
$-1.08
2025-12-31
$-3.80
2025-09-30
$-10.81
息稅折舊攤銷前利潤
2026-06-30
-$2.99M
2026-03-31
-$1.59M
2025-12-31
-$2.15M
2025-09-30
-$1.83M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
-80.77%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$0
$0
營業支出
$2.99M
$1.59M
$2.15M
$1.83M
淨利潤
-$3.02M
-$1.63M
-$2.19M
-$1.87M
淨利潤率
--
--
--
--
每股收益
$-0.76
$-1.08
$-3.80
$-10.81
息稅折舊攤銷前利潤
-$2.99M
-$1.59M
-$2.15M
-$1.83M
有效稅率
--
--
--
-80.77%
常見問題
ENVB is the ticker symbol for Enveric Biosciences, Inc., a biotechnology company. It focuses on developing therapeutics for mental health and oncology-related indications. The company is publicly traded in the United States. For the most current corporate details, including recent developments or subsidiary information, refer to the latest ENVB profile data shown on this page.
The latest ENVB stock price is continuously updated and displayed at the top of this page. Because prices change throughout the trading day, the most accurate current quote, along with any change and percentage move, is the one shown in the live data section. Use that displayed price rather than relying on any static figure.
ENVB is a small-cap biotechnology stock, a category that often experiences significant price swings. Volatility can be driven by clinical trial updates, regulatory news, financing activities, and changes in investor sentiment. The page displays metrics such as recent price range and trading volume that can help gauge the stock's recent volatility. For the latest volatility-related data, review the current market information shown on this page.
Valuation for ENVB can be assessed through several approaches, though traditional metrics like the price-to-earnings ratio may not be meaningful if the company is not yet profitable. Investors often look at price-to-book, enterprise value, cash position, and pipeline potential. The page provides available valuation metrics for ENVB. Because biotech valuations can hinge on clinical and regulatory milestones, review the latest financial data and company filings shown here.
Key risks for ENVB include clinical trial failures, regulatory setbacks, reliance on future financing, and competition in the biotechnology sector. As a smaller company, it may also face limited liquidity, share dilution, and dependence on key personnel. Macroeconomic factors and shifts in biotech investor sentiment can add further uncertainty. The specific risk factors are detailed in the company's SEC filings, which are linked from this page.
ENVB's earnings reports, including quarterly and annual results, are typically available through the company's investor relations website and SEC filings such as 10-Q and 10-K reports. This stock page may also provide links to earnings dates, historical financials, and related news. For the most recent earnings figures and upcoming report dates, check the financial data section displayed on this page.